IVL-Facilitated Transfemoral TAVR
Study Now Published
MINIMIZE TRAUMA – Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
OPTIMIZE OUTCOMES – Optimize outcomes while reducing complications and cost escalation
SIMPLIFY PROCEDURES – Simple and intuitive system that makes complex calcified procedures more predictable
The First Applications of
Learn more about the potential of IVL in patients with aortic stenosis (AS) or IVL as a means to facilitate transfemoral access and avoid alternative routes by clicking on one of the below:
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
This new #ShockwaveIVL post has everything: a hot-off-the-press infographic featuring data on #BTK calcium & recoil… https://t.co/vPG44fjm7k
That’s how it’s done! Picture perfect stand-alone #ShockwaveIVL case by Dr. @HCrespoSotoMD at @AtriumHealth in Char… https://t.co/wnA1gzWxRy
Non-healing wound, heavily calcified #SFA, pop & tibials confirmed on #IVUS. Treated with 4x40 #ShockwaveIVL & fini… https://t.co/1r6yJLvEGr
Get up to speed…the speed of sound with #ShockwaveIVL! Register to stay apprised of the latest news, clinical evide… https://t.co/WFmij8VpgU
Did a double take on this stunning result by Dr. Mark Picone at Heart Hospital of Austin!
Antegrade approach, Righ… https://t.co/xE1tflbfJA
“Which Way to the Foot?” Learn tools & techniques for navigating popliteal occlusions, including #ShockwaveIVL, fro… https://t.co/svHqg9y4y4
How do you size #ShockwaveIVL in a large #LeftMain? Hear perspective from Dr. @jcspratt about his philosophy and ot… https://t.co/n8t3VcAvrA
For physicians in Europe catching up on #SCAI2020 presentations, learn more about #ShockwaveIVL for coronary use an… https://t.co/RdTATmUFJn
Beautiful result on a really tricky lesion, Dr. @CarlosGuevaraIR! Thanks for sharing your algorithm and success – k… https://t.co/WxnqvnNLee
Kudos to the #DISRUPTPADII investigators & core lab as it was named the best #PAD study in the Best of @CCIJournal… https://t.co/c0AOIpLtGo
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
